Bibliographic Details
| Title: |
Nanomedicines for an Enhanced Immunogenic Cell Death-Based In SituCancer Vaccination Response |
| Authors: |
Zhao, Caiyan, Wang, Changrong, Shan, Wenbo, Wang, Zhongliang, Chen, Xiaoyuan, Deng, Hongzhang |
| Source: |
Accounts of Chemical Research; March 2024, Vol. 57 Issue: 6 p905-918, 14p |
| Abstract: |
Cancer vaccines have shown tremendous potential in preventing and treating cancer by providing immunogenic antigens to initiate specific tumor immune responses. An in situvaccine prepared from an autologous tumor can mobilize a patient’s own tumor cell lysate as a reservoir of specific antigens, thus triggering a broad immune response and diverse antitumor immunity in an individually tailored manner. Its efficacy is much better than that of conventional vaccines with a limited number of epitopes. Several conventional therapies, including radiotherapy (RT), chemotherapeutics, photodynamic therapy (PDT), and photothermal therapy (PTT) can activate an anticancer in situvaccine response by inducing immunogenic cell death (ICD), triggering the exposure of tumor-associated antigens (TAAs), cancerous testis antigens, neoantigens, and danger-associated molecular patterns (DAMPs) with low cost. However, the immunogenicity of dying tumor cells is low, making released antigens and DAMPs insufficient to initiate a robust immune response against malignant cancer. Moreover, the immunosuppressive tumor microenvironment (TME) severely hinders the infiltration and sensitization of effector immune cells, causing tolerogenic immunological effects. |
| Database: |
Supplemental Index |
